Education
About Us
Working with TipRanks
Follow Us
Glenmark Pharmaceuticals Limited (IN:GLENMARK)
:GLENMARK
Total Valuation
Glenmark Pharmaceuticals Limited has a market cap or net worth of ₹447.32B. The enterprise value is ―.
Market Cap₹447.32B
Enterprise Value―
Share Statistics
Glenmark Pharmaceuticals Limited has 282,200,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding282,200,800
Owned by Insiders―
Owned by Institutions0.05%
Financial Efficiency
Glenmark Pharmaceuticals Limited’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -329.12%.
Return on Equity (ROE)-0.19
Return on Assets (ROA)-0.10
Return on Invested Capital (ROIC)-329.12%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.82
Inventory Turnover3.40
Valuation Ratios
The current PE Ratio of Glenmark Pharmaceuticals Limited is -18.46. Glenmark Pharmaceuticals Limited’s PEG ratio is -2.77.
PE Ratio-18.46
PS Ratio0.00
PB Ratio4.60
Price to Fair Value3.53
Price to FCF132.09
Price to Operating Cash Flow132.10
PEG Ratio-2.77
Income Statement
In the last 12 months, Glenmark Pharmaceuticals Limited had revenue of 118.13B and earned -15.02B in profits. Earnings per share was -53.22.
Revenue118.13B
Gross Profit32.59B
Operating Income6.50B
Pretax Income364.95M
Net Income-15.02B
EBITDA11.34B
Earnings Per Share (EPS)-53.22
Cash Flow
In the last 12 months, operating cash flow was 5.77B and capital expenditures 0.00, giving a free cash flow of 5.77B billion.
Operating Cash Flow5.77B
Free Cash Flow5.77B
Free Cash Flow per Share20.45
Dividends & Yields
Glenmark Pharmaceuticals Limited pays an annual dividend of ₹2.5, resulting in a dividend yield of 0.16%
Dividend Per Share₹2.5
Dividend Yield0.16%
Payout Ratio5.28%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.95
52-Week Price Change32.25%
50-Day Moving Average1.44K
200-Day Moving Average1.54K
Relative Strength Index (RSI)74.46
Average Volume (3m)34.76K
Important Dates
Glenmark Pharmaceuticals Limited upcoming earnings date is Aug 8, 2025, TBA Not Confirmed.
Last Earnings DateMay 23, 2025
Next Earnings DateAug 8, 2025
Ex-Dividend DateSep 13, 2024
Financial Position
Glenmark Pharmaceuticals Limited as a current ratio of 1.28, with Debt / Equity ratio of 21.09%
Current Ratio1.28
Quick Ratio0.84
Debt to Market Cap0.04
Net Debt to EBITDA-0.38
Interest Coverage Ratio1.22
Taxes
In the past 12 months, Glenmark Pharmaceuticals Limited has paid 18.67B in taxes.
Income Tax18.67B
Effective Tax Rate51.17
Enterprise Valuation
Glenmark Pharmaceuticals Limited EV to EBITDA ratio is 24.06, with an EV/FCF ratio of -23.45.
EV to Sales2.31
EV to EBITDA24.06
EV to Free Cash Flow-23.45
EV to Operating Cash Flow-102.82
Balance Sheet
Glenmark Pharmaceuticals Limited has ₹16.59B in cash and marketable securities with ₹0.00 in debt, giving a net cash position of -₹16.59B billion.
Cash & Marketable Securities₹16.59B
Total Debt₹0.00
Net Cash-₹16.59B
Net Cash Per Share-₹58.80
Tangible Book Value Per Share₹230.82
Margins
Gross margin is 57.31%, with operating margin of 5.34%, and net profit margin of -12.71%.
Gross Margin57.31%
Operating Margin5.34%
Pretax Margin0.31%
Net Profit Margin-12.71%
EBITDA Margin9.60%
EBIT Margin4.68%
Analyst Forecast
The average price target for Glenmark Pharmaceuticals Limited is ₹1,785.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target₹1,785.00
Price Target Upside25.83% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―